Alamar Biosciences, Inc. (ALMR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Quarterly

0 15M 30M 45M Q1 '25: 13.1M Q2 '25: 16.2M Q1 '26: 26M Q2 '26: 29.4M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 7M 14M 21M Q1 '25: 6.4M Q2 '25: 8.6M Q1 '26: 14.5M Q2 '26: 17.7M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q1 '25: -8.6M Q2 '25: -7.9M Q1 '26: -12.3M Q2 '26: -13.5M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Net Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '25: -7.7M Q2 '25: -7M Q1 '26: -21.3M Q2 '26: -13.2M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 4M 8M 12M Q1 '25: 6.7M Q2 '25: 7.6M Q1 '26: 11.6M Q2 '26: 11.7M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q1 '25: -13.1M Q2 '25: -11.9M Q1 '26: -20.3M Q2 '26: -11.3M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '25: -13.6M Q2 '25: -12.6M Q1 '26: -20.9M Q2 '26: -15M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '25: 11.3M Q2 '25: 11.4M Q1 '26: 12.3M Q2 '26: 58.7M Q1 '25 Q2 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.